Lacidipine

Drug Profile

Lacidipine

Alternative Names: Aponil; Caldine; GR 43659; GR 43659X; GX 1048; Lacimen; Lacipil; Lacirex; Midotens; Motens; SN 305; Tens; Viapres

Latest Information Update: 18 Jan 2008

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator GlaxoSmithKline
  • Class Antihypertensives; Dihydropyridines; Small molecules
  • Mechanism of Action Calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hypertension

Most Recent Events

  • 10 Nov 2014 Biomarkers information updated
  • 27 Jan 2003 The ELSA study has been added to the Hyperlipidaemia and Vascular Disorders therapeutic trials sections
  • 22 May 2002 The COHORT study has been added to the adverse events section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top